Just like the old American pastime, “let’s play with chinese burritos”, this game has become a crowd favorite as of late. I just booked a one week 25% gain in BLCM and already have a 3.5% gain in NDRM. In addition to those, I own some other names, all designated for longer term investments: JAZZ, ICPT and SGEN. However, I believe it’s time to play this sector until the wheels fall off the wagon and all of its passenger tossed idly into a swamp strewn with hungry crocodiles.
Using The PPT‘s proprietary momentum algorithms, here are some biotechs that are fixing to exploud to the upside.
CALA
NDRM
CRL
ZFGN
ENDP
AGIO
AUXL
BLRX
MRTX
KMDA
HALO
ITS TIME TO BY THE EARL SECTOR
a game
Its more like, “EARL TOUCHES YOUR PRIVATES” the game
Already own it.
Biotechs are far better.
Who is the best Bio fund manager?
Baker Brothers.
Long GEVA, SGEN and others.
Like that CALA, NDRM, ENDP, & BLRX
.
If you feel compelled to play Biotech …
Why not just get LONG the ETFs ?
—–
$BBH
… or …
$BIB if you want to add leverage !
.
.
Guess that would be too boring !
.
Fly do you still think Juno will be the best biotech investment for 2015? So far you have been right
FGEN, CARA, ALNY
Thoughts on CELG sir?
$GILD Playa
Yes i own a bunch. I consider it big pharma
You must be hugely ahead of last year’s performance. Maybe you should shut it down for the year.
Orbimed, Perceptive Advisors, RA Capital worth a peak in their 13-f
Play it fast and tight. The GILD pricing news is the kiss of death. The old rule this land, and they will not be denied cheap drugs. Once the last home gamer goes all in this trade is over.
PJP & XLV
HALO is holding investor & analyst meeting today. The stock is a Type 1 Short Squeeze in our work, i.e. the squeeze is on. But there have been five times that short intensity has reached heavy and the shorts were squeezed three times on average for 15.70%. When the shorts were correct they made -34.20%. The overall average is a move of -16.0%. So far shorts have been squeezed 1.97% since our short intensity rank got above 80% on September 24, 2014. THIS COULD BE A CASE WHERE THE SHORTS ARE CORRECT. Respectfully, G
GALT after phase 1 NASH study results?